Continuous Interscalene Blocks and Rebound Pain

NOT YET RECRUITING

NCT07770165

NA

Sponsor: University of Calgary

Summary

The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty. Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."

Official title: Evaluation of the Effect of Continuous Interscalene Blocks on Rebound Pain Compared to Single-Shot Interscalene Blocks in Total Shoulder Arthroplasty : A Randomized-Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

154

Start Date

2026-10

Completion Date

2027-05

Last Updated

2026-08-19

Healthy Volunteers

No

Conditions

Total Shoulder Arthroplasty Reverse Total Shoulder Arthroplasty Interscalene Analgesia Interscalene Blocks Interscalene Nerve Block Orthopedic Surgery Patients Locoregional Anaesthesia Rebound Pain

Interventions

DRUG

Continuous interscalene nerve block

This Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate.

DRUG

Interscalene Block

This control group will receive a single shot interscalene block with 20 mL of ropivicaine 0.2%.

Locations (1)

South Health Campus

Calgary, Alberta, Canada

Clinical Research Directory